F
Fluxus at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Fluxus brings 2 presentations to IDWeek 2026 in Washington. Its program focuses on ultrasensitive diagnostic tests for tuberculosis and Clostridioides difficile infection. One study quantifies the TB marker LAM in urine at the single-molecule level, and another reports that its toxin assay outperforms standard methods for diagnosing C. difficile.
| Organization | IDWeek 2026 Attendance |
|---|---|
F Fluxus Sunnyvale, CA | |
Fujirebio subsidiary developing ultrasensitive single-molecule counting assays, including a C. difficile toxin test. | Poster Thu Oct 22 12:15pm–1:30pm Ultrasensitive Single‑Molecule Urine LAM Quantification Achieves High Accuracy for TB Detection Talk Sat Oct 24 11:18am–11:30am Redefining CDI Diagnosis: Superior Accuracy of an Ultrasensitive Toxin Assay Compared to Standard Diagnostic Methods and CCNA Diagnostics and diagnostic stewardship |
Instantly find 20 buyers from Fluxus
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction